Do we need pharmacological therapy for atrial fibrillation in the ablation era?
Management of atrial fibrillation (AF) remains one of the most difficult problems of modern cardiology. Pharmacological antiarrhythmic therapy is used both for termination of episodes of AF and for prevention of AF recurrences. Recently, major trials have compared the strategy of maintenance of sinus rhythm, called rhythm control, with the strategy of heart rate control during AF and found that the rhythm control strategy was not superior to rate control in terms of mortality. Although subsequent analysis identified rhythm control as a factor of improved survival, these large trials have markedly influenced the management of AF. One of the hypotheses explaining the non-superiority of the rhythm control strategy was that the benefit of sinus rhythm was offset by the side effects of antiarrhythmic agents. As a consequence, attention was directed to non-pharmacological therapies, particularly to catheter ablation of the trigger or/and the atrial substrate using radiofrequency current or cryothermia. However, despite the reported good results of various types of interventions in the hands of highly qualified teams, catheter ablation cannot be applied to all patients with AF or to all types of AF. Furthermore, catheter ablation of AF requires sophisticated electrophysiologic laboratories equipped with expensive imaging techniques and a well-trained staff that cannot be available in sufficient number to cover the growing epidemic of AF with acceptable efficacy and safety even in rich countries. Therefore, there is still a need for pharmacological therapy aimed at the prevention of AF recurrences for the majority of AF patients. So far, attempts to provide the physician with efficient antiarrhythmic agents having a good safety profile have not been successful. However, recent research resulted in promising new approaches including prevention of AF using converting enzyme inhibitors or angiotensin 2 receptor blockers, new antiarrhythmic agents with multichannel effects such as dronedarone and tedisamil and atrial specific agents that theoretically should have no ventricular proarrhythmic effect as they target specific atrial channels such as IKAch and IKur which are absent at the ventricular level. Other possible mechanisms of AF that represent potential targets, such as modification of stretch-activated ion channels, intervention of altered connexin expression and altered gap-junctional conductance, are currently investigated.
KeywordsAtrial fibrillation Ablation Pharmacological therapy
Unable to display preview. Download preview PDF.
- 1.Lévy, S., Breithardt, G., Campbell, R. W., Camm, A. J., Daubert, J. C., Allessie, M., et al. (1998). Atrial fibrillation: Current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. European Heart Journal, 19, 1294–1320.PubMedCrossRefGoogle Scholar
- 3.Fuster, V., Ryden, L., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., et al. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology for Practice Guidelines and Policy Conferences. European Heart Journal, 22, 1852–1923.PubMedCrossRefGoogle Scholar
- 17.Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Journal of the American College of Cardiology, 48, e149–e246 (Aug 15).CrossRefGoogle Scholar
- 19.Capucci, A., Tizziano, L., Boriani, G., Trisolino, G., Binetti, N., Cavazza, M., et al. (1992). Effectiveness of loading oral flecainide for converting recent–onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. American Journal of Cardiology, 70, 69–72.PubMedCrossRefGoogle Scholar
- 21.Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996). Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation, 1(94), 1613–1621.Google Scholar
- 22.Pratt, C. M., Singh, S. N., Al-Khalidi, H. R., Brum, J. M., Holroyde, M. J., Marcello, S. R., et al. (2004). The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. Journal of the American College of Cardiology, 43, 1211–1216.PubMedCrossRefGoogle Scholar
- 30.Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., et al. (2001). Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 104, 2608–2616.PubMedGoogle Scholar
- 33.Madrid, A. H., Peng, J., Zamora, J., Marin, I., Bernal, E., Escobar, C., et al. (2004). The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials. PACE, 27, 1405–1410.PubMedGoogle Scholar
- 34.Goldstein, R. N., Khrestian, C., Carlsson, L., & Waldo, A. L. (2004). Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. Journal of Cardiovascular Electrophysiology, 1444–1450.Google Scholar
- 37.Roy, D., Rowe, B. H., Stiell, I. G., Coutu, B., Ip, J. H., Phaneuf, D., et al. CRAFT Investigators (2004). A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. Journal of the American College of Cardiology, 44, 2355–2361.PubMedCrossRefGoogle Scholar
- 38.Gilmour, R. F., & Zipes, D. P. (2004). Mechanisms of disease: New mechanisms of antiarrhythmic actions. Natural Clinical Practice. Cardiovascular Medicine, 1, 37–41.Google Scholar